{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:27:16Z","timestamp":1787311636171,"version":"build-2736575974"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007109","name":"Universit\u00e0 degli Studi di Ferrara","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Pregnancy in acromegaly is a rare event. Its management is still a challenge given the lack of data, the risk of tumor progression and maternal-fetal complications. This study aims to evaluate the impact of different treatment strategies, particularly somatostatin receptor ligands (SRL) and pegvisomant (PEG), on maternal and neonatal outcomes through a comprehensive review of the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a narrative review of the literature. A PubMed search was performed using the keywords \u201cacromegaly AND pregnancy\u201d, combined with treatment-related terms, covering publications from January 1, 1988, to January 21, 2026. No publication type restrictions were applied. Additional articles were identified through manual reference screening. Articles published in English and Italian were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 44 articles were identified, comprising 120 patients and 134 pregnancies; we further contribute an additional case of pregnancy with pasireotide exposure, representing the third reported case of pasireotide exposure during pregnancy. Medical management was categorized as follows: treatment withdrawal before conception (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200940), discontinuation upon pregnancy confirmation (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200947), and continuation or modification throughout gestation (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200930). Symptom worsening occurred in 16.7\u201340%. Maternal complications included gestational diabetes (5.6\u201318.8%) and pre-eclampsia (2.8\u201310.3%). Overall, fetal outcomes were favorable, with only one congenital malformation. Breastfeeding was successfully achieved in most cases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pregnancy in acromegaly is generally characterized by clinical stability, supporting the safety of treatment withdrawal upon conception in most patients. While early therapy discontinuation is standard, SRL and\/or PEG treatment is a viable option for patients requiring tumor and biochemical control. Individualized multidisciplinary management is essential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12020-026-04761-x","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:31:41Z","timestamp":1787308301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management and safety of somatostatin receptor ligands and pegvisomant in pregnant women with acromegaly: a narrative review of the literature"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5419-545X","authenticated-orcid":false,"given":"Margherita","family":"Medici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5687-2208","authenticated-orcid":false,"given":"Valentino","family":"Marino Picciola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Comune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cicale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8408-7796","authenticated-orcid":false,"given":"Maria Chiara","family":"Zatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7911-9770","authenticated-orcid":false,"given":"Maria Rosaria","family":"Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"4761_CR1","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMra2409076","volume":"393","author":"A Giustina","year":"2025","unstructured":"A. Giustina, A. Colao, Acromegaly. N Engl. J. Med. 393, 1926\u20131939 (2025). https:\/\/doi.org\/10.1056\/NEJMra2409076","journal-title":"N Engl. J. Med."},{"key":"4761_CR2","doi-asserted-by":"publisher","first-page":"K21","DOI":"10.1530\/EJE-18-0688","volume":"180","author":"AM Hannon","year":"2019","unstructured":"A.M. Hannon, T. O\u2019Shea, C.A. Thompson et al., Pregnancy in acromegaly is safe and is associated with improvements in IGF-1 concentrations. Eur. J. Endocrinol. 180, K21\u2013K29 (2019). https:\/\/doi.org\/10.1530\/EJE-18-0688","journal-title":"Eur. J. Endocrinol."},{"key":"4761_CR3","doi-asserted-by":"publisher","first-page":"102856","DOI":"10.1016\/j.arcmed.2023.102856","volume":"54","author":"J Kerbel","year":"2023","unstructured":"J. Kerbel, A. Cano-Zaragoza, R. Espinosa-Dorado et al., Real World Data on the Epidemiology, Diagnosis, and Treatment of Acromegaly: A Registries-based Approach. Arch. Med. Res. 54, 102856 (2023). https:\/\/doi.org\/10.1016\/j.arcmed.2023.102856","journal-title":"Arch. Med. Res."},{"key":"4761_CR4","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1210\/jcem.84.8.5858","volume":"84","author":"GA Kaltsas","year":"1999","unstructured":"G.A. Kaltsas, J.J. Mukherjee, P.J. Jenkins et al., Menstrual Irregularity in Women with Acromegaly. J. Clin. Endocrinol. Metab. 84, 2731\u20132735 (1999)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4761_CR5","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1210\/clinem\/dgad042","volume":"108","author":"R Pirchio","year":"2023","unstructured":"R. Pirchio, R.S. Auriemma, L.F.S. Grasso et al., Fertility in Acromegaly: A Single-Center Experience of Female Patients During Active Disease and After Disease Remission. J. Clin. Endocrinol. Metab. 108, e583\u2013e593 (2023). https:\/\/doi.org\/10.1210\/clinem\/dgad042","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4761_CR6","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/EJE-16-1059","volume":"177","author":"J Abucham","year":"2017","unstructured":"J. Abucham, M.D. Bronstein, M.L. Dias, Management of Endocrine Disease: Acromegaly and pregnancy: a contemporary review. Eur. J. Endocrinol. 177, R1\u2013R12 (2017). https:\/\/doi.org\/10.1530\/EJE-16-1059","journal-title":"Eur. J. Endocrinol."},{"key":"4761_CR7","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/cen.13599","volume":"88","author":"RS Jallad","year":"2018","unstructured":"R.S. Jallad, I. Shimon, M. Fraenkel et al., Outcome of pregnancies in a large cohort of women with acromegaly. Clin. Endocrinol. (Oxf). 88, 896\u2013907 (2018). https:\/\/doi.org\/10.1111\/cen.13599","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"4761_CR8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s11102-022-01208-0","volume":"25","author":"DB Bandeira","year":"2022","unstructured":"D.B. Bandeira, T.O.F. Olivatti, F. Bolfi et al., Acromegaly and pregnancy: a systematic review and meta-analysis. Pituitary. 25, 352\u2013362 (2022). https:\/\/doi.org\/10.1007\/s11102-022-01208-0","journal-title":"Pituitary"},{"key":"4761_CR9","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"L. Katznelson, E.R. Laws, S. Melmed et al., Acromegaly: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 99, 3933\u20133951 (2014). https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4761_CR10","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.beem.2011.05.011","volume":"25","author":"ME Molitch","year":"2011","unstructured":"M.E. Molitch, Prolactinoma in pregnancy. Best Pract. Res. Clin. Endocrinol. Metab. 25, 885\u2013896 (2011). https:\/\/doi.org\/10.1016\/j.beem.2011.05.011","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"4761_CR11","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1056\/NEJM198903093201016","volume":"320","author":"A Landolt","year":"1989","unstructured":"A. Landolt, Successful Pregnancy in a Previously Infertile Woman Treated with SMS-201\u2013995 for Acromegaly. N. Engl. J. Med. 320, 671\u2013672 (1989). https:\/\/doi.org\/10.1056\/NEJM198903093201016","journal-title":"N. Engl. J. Med."},{"key":"4761_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF03349537","volume":"13","author":"M Montini","year":"1990","unstructured":"M. Montini, G. Pagani, D. Gianola et al., Acromegaly and primary amenorrhea: ovulation and pregnancy induced by SMS 201\u2013995 and bromocriptine. J. Endocrinol. Invest. 13, 193\u2013193 (1990). https:\/\/doi.org\/10.1007\/BF03349537","journal-title":"J. Endocrinol. Invest."},{"key":"4761_CR13","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1210\/jcem.82.9.4257","volume":"82","author":"A Colao","year":"1997","unstructured":"A. Colao, M. Bartolomeno, D. Ferone, G. Lombardi, Acromegaly. J. Clin. Endocrinol. Metab. 82, 2777\u20132781 (1997). https:\/\/doi.org\/10.1210\/jcem.82.9.4257","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4761_CR14","first-page":"727","volume":"83","author":"V Herman-Bonert","year":"1998","unstructured":"V. Herman-Bonert, M. Seliverstov, S. Melmed, Pregnancy in Acromegaly: Successful Therapeutic Outcome. J. Clin. Endocrinol. Metab. 83, 727\u2013731 (1998)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4761_CR15","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1210\/jcem.84.4.5625-5","volume":"84","author":"E De Menis","year":"1999","unstructured":"De E. Menis, D. Billeci, E. Marton, Uneventful Pregnancy in an Acromegalic Patient Treated with Slow-Release Lanreotide: A Case Report. J. Clin. Endocrinol. Metab. 84, 1489 (1999)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4761_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/s0020-7292(98)00221-5","volume":"65","author":"J Mozas","year":"1999","unstructured":"J. Mozas, E. Ocon, A.J. Herruzo, Successful pregnancy in a woman with acromegaly treated with somatostatin analog (octreotide) prior to surgical resection. Int. J. Gynaecol. Obstet. 65, 71\u201373 (1999). https:\/\/doi.org\/10.1016\/s0020-7292(98)00221-5","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"4761_CR17","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/s0029-7844(98)00461-x","volume":"93","author":"K Takeuchi","year":"1998","unstructured":"K. Takeuchi, T. Funakoshi, S. Oomori, T. Maruo, Successful pregnancy in an acromegalic woman treated with octreotide. Obstet. Gynecol. 93, 848 (1998). https:\/\/doi.org\/10.1016\/s0029-7844(98)00461-x","journal-title":"Obstet. Gynecol."},{"key":"4761_CR18","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1046\/J.1365-2265.2000.01058.X","volume":"53","author":"T Hierl","year":"2000","unstructured":"T. Hierl, R. Ziegler, C. Kasperk, Pregnancy in persistent acromegaly. Clin. Endocrinol. (Oxf). 53, 262\u2013263 (2000). https:\/\/doi.org\/10.1046\/J.1365-2265.2000.01058.X","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"4761_CR19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.4158\/EP.6.2.148","volume":"6","author":"JM Neal","year":"2000","unstructured":"J.M. Neal, Successful Pregnancy In A Woman With Acromegaly Treated With Octreotide. Endocr. Pract. 6, 148\u2013150 (2000). https:\/\/doi.org\/10.4158\/EP.6.2.148","journal-title":"Endocr. Pract."},{"key":"4761_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1046\/j.1365-2265.2001.01304.x","volume":"55","author":"M Fassnacht","year":"2001","unstructured":"M. Fassnacht, B. Capeller, W. Arlt et al., Octreotide LAR\u00ae treatment throughout pregnancy in an acromegalic woman. Clin. Endocrinol. (Oxf). 55, 411\u2013415 (2001). https:\/\/doi.org\/10.1046\/j.1365-2265.2001.01304.x","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"4761_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4065\/77.3.297-a","volume":"77","author":"N Mikhail","year":"2002","unstructured":"N. Mikhail, Octreotide Treatment of Acromegaly During Pregnancy. Mayo Clin. Proc. 77, 297\u2013298 (2002). https:\/\/doi.org\/10.4065\/77.3.297-a","journal-title":"Mayo Clin. Proc."},{"key":"4761_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/00019616-200301000-00005","volume":"13","author":"O Serri","year":"2003","unstructured":"O. Serri, G. Lanoie, Successful Pregnancy in a Woman With Acromegaly Treated With Octreotide Long-acting Release. : Endocrinologist. 13, 17\u201319 (2003). https:\/\/doi.org\/10.1097\/00019616-200301000-00005","journal-title":": Endocrinologist"},{"key":"4761_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1055\/s-2005-873004","volume":"114","author":"A Atmaca","year":"2006","unstructured":"A. Atmaca, S. Dagdelen, T. Erbas, Follow-Up of Pregnancy in Acromegalic Women: Different Presentations and Outcomes. Exp. Clin. Endocrinol. Diabetes. 114, 135\u2013139 (2006). https:\/\/doi.org\/10.1055\/s-2005-873004","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"4761_CR24","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1530\/eje.1.02215","volume":"155","author":"R Cozzi","year":"2006","unstructured":"R. Cozzi, R. Attanasio, M. Barausse, Pregnancy in acromegaly: a one-center experience. Eur. J. Endocrinol. 155, 279\u2013284 (2006). https:\/\/doi.org\/10.1530\/eje.1.02215","journal-title":"Eur. J. Endocrinol."},{"key":"4761_CR25","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10815-006-9077-6","volume":"23","author":"A Qureshi","year":"2006","unstructured":"A. Qureshi, E. Kalu, G. Ramanathan et al., IVF\/ICSI in a woman with active acromegaly: Successful outcome following treatment with pegvisomant. J. Assist. Reprod. Genet. 23, 439\u2013442 (2006). https:\/\/doi.org\/10.1007\/s10815-006-9077-6","journal-title":"J. Assist. Reprod. Genet."},{"key":"4761_CR26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1507\/endocrj.53.209","volume":"53","author":"T Takano","year":"2006","unstructured":"T. Takano, J. Saito, A. Soyama et al., Normal Delivery Following an Uneventful Pregnancy in a Japanese Acromegalic Patient after Discontinuation of Octreotide Long Acting Release Formulation at an Early Phase of Pregnancy. Endocr. J. 53, 209\u2013212 (2006). https:\/\/doi.org\/10.1507\/endocrj.53.209","journal-title":"Endocr. J."},{"key":"4761_CR27","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1080\/00016340600676532","volume":"85","author":"P Wiesli","year":"2006","unstructured":"P. Wiesli, C. Zwimpfer, J. Zapf, C. Schmid, Pregnancy-induced changes in insulin\u2010like growth factor I (IGF\u2010I), insulin\u2010like growth factor binding protein 3 (IGFBP\u20103), and acid\u2010labile subunit (ALS) in patients with growth hormone (GH) deficiency and excess. Acta Obstet. Gynecol. Scand. 85, 900\u2013905 (2006). https:\/\/doi.org\/10.1080\/00016340600676532","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"4761_CR28","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1210\/jc.2007-0997","volume":"92","author":"SR Brian","year":"2007","unstructured":"S.R. Brian, M. Bidlingmaier, M.P. Wajnrajch et al., Treatment of Acromegaly with Pegvisomant during Pregnancy: Maternal and Fetal Effects. J. Clin. Endocrinol. Metab. 92, 3374\u20133377 (2007). https:\/\/doi.org\/10.1210\/jc.2007-0997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4761_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/BF03345599","volume":"31","author":"SL Lau","year":"2008","unstructured":"S.L. Lau, S. McGrath, D. Evain-Brion, R. Smith, Clinical and biochemical improvement in acromegaly during pregnancy. J. Endocrinol. Invest. 31, 255\u2013261 (2008). https:\/\/doi.org\/10.1007\/BF03345599","journal-title":"J. Endocrinol. Invest."},{"key":"4761_CR30","doi-asserted-by":"publisher","first-page":"4680","DOI":"10.1210\/jc.2009-2331","volume":"95","author":"P Caron","year":"2010","unstructured":"P. Caron, S. Broussaud, J. Bertherat et al., Acromegaly and Pregnancy: A Retrospective Multicenter Study of 59 Pregnancies in 46 Women. J. Clin. Endocrinol. Metab. 95, 4680\u20134687 (2010). https:\/\/doi.org\/10.1210\/jc.2009-2331","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4761_CR31","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/j.1365-2265.2009.03706.x","volume":"72","author":"P Maffei","year":"2010","unstructured":"P. Maffei, G. Tamagno, G.B. Nardelli et al., Effects of octreotide exposure during pregnancy in acromegaly. Clin. Endocrinol. (Oxf). 72, 668\u2013677 (2010). https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03706.x","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"4761_CR32","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3803\/EnM.2010.25.3.213","volume":"25","author":"SK Kim","year":"2010","unstructured":"S.K. Kim, J.H. Jung, J.H. Kim et al., Sustained Maintenance of Normal Insulin-like Growth Factor-I during Pregnancy and Successful Delivery in an Acromegalic Patient with Octreotide-LAR\u00ae Treatment. Endocrinol. Metab. 25, 213 (2010). https:\/\/doi.org\/10.3803\/EnM.2010.25.3.213","journal-title":"Endocrinol. Metab."},{"key":"4761_CR33","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1507\/endocrj.K10E-069","volume":"57","author":"A Shimatsu","year":"2010","unstructured":"A. Shimatsu, T. Usui, T. Tagami et al., Suppressed levels of growth hormone and insulin-like growth factor-1 during successful pregnancy in persistent acromegaly. Endocr. J. 57, 551\u2013553 (2010). https:\/\/doi.org\/10.1507\/endocrj.K10E-069","journal-title":"Endocr. J."},{"key":"4761_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/WNQ.0b013e3182277dc6","volume":"22","author":"AN Torun","year":"2012","unstructured":"A.N. Torun, F. Torun, A Healthy Newborn Delivered From an Active Acromegalic Woman Receiving High-dose Long-acting Octreotide During her Entire Pregnancy. Neurosurg. Q. 22, 41\u201342 (2012). https:\/\/doi.org\/10.1097\/WNQ.0b013e3182277dc6","journal-title":"Neurosurg. Q."},{"key":"4761_CR35","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1365-2265.2011.04180.x","volume":"76","author":"S Cheng","year":"2012","unstructured":"S. Cheng, L. Grasso, J.A. Martinez-Orozco et al., Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature. Clin. Endocrinol. (Oxf). 76, 264\u2013271 (2012). https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04180.x","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"4761_CR36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11102-011-0330-3","volume":"15","author":"V Cheng","year":"2012","unstructured":"V. Cheng, C. Faiman, L. Kennedy et al., Pregnancy and acromegaly: a review. Pituitary. 15, 59\u201363 (2012). https:\/\/doi.org\/10.1007\/s11102-011-0330-3","journal-title":"Pituitary"},{"key":"4761_CR37","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1507\/endocrj.EJ11-0306","volume":"59","author":"L Kasuki","year":"2012","unstructured":"L. Kasuki, L.V. Neto, C.M. Takiya, M.R. Gadelha, Growth of an aggressive tumor during pregnancy in an acromegalic patient. Endocr. J. 59, 313\u2013319 (2012). https:\/\/doi.org\/10.1507\/endocrj.EJ11-0306","journal-title":"Endocr. J."},{"key":"4761_CR38","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1530\/EJE-13-0460","volume":"170","author":"M Dias","year":"2014","unstructured":"M. Dias, C. Boguszewski, M. Gadelha et al., Acromegaly and pregnancy: a prospective study. Eur. J. Endocrinol. 170, 301\u2013310 (2014). https:\/\/doi.org\/10.1530\/EJE-13-0460","journal-title":"Eur. J. Endocrinol."},{"key":"4761_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/1753495X15598699","volume":"9","author":"A Assal","year":"2016","unstructured":"A. Assal, J. Malcolm, H. Lochnan, E. Keely, Preconception counselling for women with acromegaly: More questions than answers. Obstet. Med. 9, 9\u201314 (2016). https:\/\/doi.org\/10.1177\/1753495X15598699","journal-title":"Obstet. Med."},{"key":"4761_CR40","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s11102-016-0717-2","volume":"19","author":"O Haliloglu","year":"2016","unstructured":"O. Haliloglu, B. Dogangun, B. Ozcabi et al., General health status and intelligence scores of children of mothers with acromegaly do not differ from those of healthy mothers. Pituitary. 19, 391\u2013398 (2016). https:\/\/doi.org\/10.1007\/s11102-016-0717-2","journal-title":"Pituitary"},{"key":"4761_CR41","doi-asserted-by":"publisher","first-page":"136","DOI":"10.25179\/tjem.2017-56497","volume":"21","author":"E \u00d6nder","year":"2017","unstructured":"E. \u00d6nder, Y. Aydin, T. Soysal et al., Acromegaly and Pregnancy: Five New Cases. Endocrinol. Res. Pract. 21, 136\u2013139 (2017). https:\/\/doi.org\/10.25179\/tjem.2017-56497","journal-title":"Endocrinol. Res. Pract."},{"key":"4761_CR42","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/09513590.2017.1404240","volume":"33","author":"D Teltayev","year":"2017","unstructured":"D. Teltayev, S. Akshulakov, N. Ryskeldiev et al., Pregnancy in women after successful acromegaly treatment, including surgical removal of pituitary adenoma and postoperative therapy using lanreotide acetate. Gynecol. Endocrinol. 33, 50\u201351 (2017). https:\/\/doi.org\/10.1080\/09513590.2017.1404240","journal-title":"Gynecol. Endocrinol."},{"key":"4761_CR43","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12020-018-1540-5","volume":"60","author":"SC Dogansen","year":"2018","unstructured":"S.C. Dogansen, S. Tanrikulu, G.Y. Yalin, S. Yarman, Female gonadal functions and ovarian reserve in patients with acromegaly: experience from a single tertiary center. Endocrine. 60, 167\u2013174 (2018). https:\/\/doi.org\/10.1007\/s12020-018-1540-5","journal-title":"Endocrine"},{"key":"4761_CR44","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/1871530318666180807160712","volume":"19","author":"F Dicuonzo","year":"2019","unstructured":"F. Dicuonzo, S. Purciariello, De A. Marco et al., Inoperable Giant Growth Hormone-secreting Pituitary Adenoma: Radiological Aspects, Clinical Management and Pregnancy Outcome. Endocr. Metab. Immune Disord Drug Targets. 19, 214\u2013220 (2019). https:\/\/doi.org\/10.2174\/1871530318666180807160712","journal-title":"Endocr. Metab. Immune Disord Drug Targets"},{"key":"4761_CR45","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-19-0019","author":"AM Hannon","year":"2019","unstructured":"A.M. Hannon, I. Frizelle, G. Kaar et al., Octreotide use for rescue of vision in a pregnant patient with acromegaly. Endocrinol. Diabetes Metab. Case Rep. (2019). https:\/\/doi.org\/10.1530\/EDM-19-0019","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"4761_CR46","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s11102-020-01050-2","volume":"23","author":"FJ Guarda","year":"2020","unstructured":"F.J. Guarda, W. Gong, A. Ghajar et al., Preconception use of pegvisomant alone or as combination therapy for acromegaly: a case series and review of the literature. Pituitary. 23, 498\u2013506 (2020). https:\/\/doi.org\/10.1007\/s11102-020-01050-2","journal-title":"Pituitary"},{"key":"4761_CR47","first-page":"433","volume":"42","author":"A Babi\u0144ska","year":"2021","unstructured":"A. Babi\u0144ska, H. Olszewska, K. Sworczak, Safe treatment with somatostatin analogues in a woman with acromegaly whilst pregnant and lactating. Pol. Merkur Lekarski. 42, 433\u2013437 (2021)","journal-title":"Pol. Merkur Lekarski"},{"key":"4761_CR48","doi-asserted-by":"publisher","first-page":"101417","DOI":"10.1016\/j.ghir.2021.101417","volume":"60\u201361","author":"L Das","year":"2021","unstructured":"L. Das, P. Dutta, B. Thirunavukkarasu et al., Course and outcomes of pregnancy in women treated for acromegaly: Discerning a contemporary cohort. Growth Horm. IGF Res. 60\u201361, 101417 (2021). https:\/\/doi.org\/10.1016\/j.ghir.2021.101417","journal-title":"Growth Horm. IGF Res."},{"key":"4761_CR49","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12902-023-01341-2","volume":"23","author":"R Jiao","year":"2023","unstructured":"R. Jiao, J. Ju, L. Wang et al., Safety of pregnancy in acromegaly patients and maternal and infant outcomes after pregnancy: single-center experience from China and review of the literature. BMC Endocr. Disord. 23, 104 (2023). https:\/\/doi.org\/10.1186\/s12902-023-01341-2","journal-title":"BMC Endocr. Disord"},{"key":"4761_CR50","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ando.2023.01.006","volume":"84","author":"M Petyt","year":"2023","unstructured":"M. Petyt, S. Grunenwald, C. Mouly et al., Healthy pregnancy in a woman with GH-secreting pituitary macroadenoma treated with pasireotide. Ann. Endocrinol. 84, 427\u2013429 (2023). https:\/\/doi.org\/10.1016\/j.ando.2023.01.006","journal-title":"Ann. Endocrinol."},{"key":"4761_CR51","doi-asserted-by":"publisher","unstructured":"J.Y. Tan, J. Chemmanam, M.G. Burt et al., Safe Continuation of Pegvisomant During Pregnancy in a Patient With Fibrous Dysplasia\/McCune-Albright Syndrome. J. Clin. Endocrinol. Metab. Case Rep. 3 (2025). https:\/\/doi.org\/10.1210\/jcemcr\/luaf095","DOI":"10.1210\/jcemcr\/luaf095"},{"key":"4761_CR52","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40619-024-01460-5","volume":"25","author":"I Comune","year":"2024","unstructured":"I. Comune, G. Cristilli, M. Verrienti et al., Acromegalia e gravidanza: gestione clinica. L\u2019Endocrinologo. 25, 299\u2013304 (2024). https:\/\/doi.org\/10.1007\/s40619-024-01460-5","journal-title":"L\u2019Endocrinologo"},{"key":"4761_CR53","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0015-0282(02)04694-0","volume":"79","author":"X Wang","year":"2003","unstructured":"X. Wang, C. Chen, L. Wang et al., Conception, early pregnancy loss, and time to clinical pregnancy: a population-based prospective study. Fertil. Steril. 79, 577\u2013584 (2003). https:\/\/doi.org\/10.1016\/S0015-0282(02)04694-0","journal-title":"Fertil. Steril."},{"key":"4761_CR54","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ecl.2024.05.012","volume":"53","author":"EA Rosenberg","year":"2024","unstructured":"E.A. Rosenberg, E.W. Seely, Update on Preeclampsia and Hypertensive Disorders of Pregnancy. Endocrinol. Metab. Clin. North. Am. 53, 377\u2013389 (2024). https:\/\/doi.org\/10.1016\/j.ecl.2024.05.012","journal-title":"Endocrinol. Metab. Clin. North. Am."},{"issue":"3","key":"4761_CR55","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-21-0462","volume":"185","author":"A Luger","year":"2021","unstructured":"A. Luger, L.H.A. Broersen, N.R. Biermasz, B.M.K. Biller, M. Buchfelder, P. Chanson, J.O.L. Jorgensen, F. Kelestimur, S. Llahana, D. Maiter, G. Mintziori, F. Petraglia, R. Verkauskiene, S.M. Webb, O.M. Dekkers, ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. Eur. J. Endocrinol. 185(3), G1\u2013G33 (2021). https:\/\/doi.org\/10.1530\/EJE-21-0462","journal-title":"Eur. J. Endocrinol."},{"issue":"11","key":"4761_CR56","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1136\/annrheumdis-2017-211384","volume":"76","author":"ME Clowse","year":"2017","unstructured":"M.E. Clowse, F. F\u00f6rger, C. Hwang, J. Thorp, R.J. Dolhain, van A. Tubergen, L. Shaughnessy, J. Simpson, M. Teil, N. Toublanc, M. Wang, T.W. Hale, Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann. Rheum. Dis. 76(11), 1890\u20131896 (2017). https:\/\/doi.org\/10.1136\/annrheumdis-2017-211384","journal-title":"Ann. Rheum. Dis."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04761-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04761-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04761-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:31:43Z","timestamp":1787308303000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04761-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4761"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04761-x","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"4 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required for review. The performed evaluations are part of the clinical routine and therefore the approval from the Ethics Committee is waived. The research was carried out in adherence to the ethical guidelines outlined in the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from our patient.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our patient has consented to the submission of the case report to the journal.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose. The authors do not have competing interests.","order":4,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"286"}}